Recombinant erythropoietin protective and related effects on brain injury in premature infants

L-M Ma1, X Si, S-F Zhai

  • 1Neonatal Department, Handan Central Hospital of Hebei Province, Handan, Hebei, China. liu_xh_HCHHP@mjc-edu.cn.

Insights

Recombinant erythropoietin shows protective effects against brain injury in premature infants, improving intellectual and psychomotor development. It also impacts cytokines but does not significantly alter blood routine indicators.

Area of Science:

  • Neonatal Medicine
  • Developmental Pediatrics
  • Pharmacology

Background:

  • Premature infants are susceptible to brain injury.
  • Early intervention is crucial for improving outcomes.

Purpose of the Study:

  • To evaluate the protective effects of recombinant erythropoietin (EPO) on brain injury in premature infants.
  • To assess EPO's impact on blood routine, liver function, and neurodevelopmental indices.

Main Methods:

  • 120 premature infants were divided into four groups: three experimental groups receiving different doses of EPO and one control group.
  • Intervention involved EPO treatment for experimental groups and conventional methods for the control group.

Main Results:

  • EPO treatment significantly reduced S-100B and IL-6 levels (p<0.05).
  • Improved neonatal behavior was observed in groups A and B compared to controls (p<0.05).
  • Intellectual development showed significant improvement at 3, 6, and 9 months post-treatment (p<0.05).
  • Liver function indices improved significantly post-treatment (p<0.05), while blood routine indicators remained unchanged.

Conclusions:

  • Recombinant erythropoietin demonstrates a protective effect on brain injury in premature infants.
  • EPO improves intellectual development, mental development index (MDI), and psychomotor development index (PDI).
  • EPO effectively modulates related cytokines and shows significance in treating brain injury without affecting blood routine indicators.
Abstract